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Patient-Derived Xenografts (PDXs), entailing implantation of cancer specimens in immunocompromised mice, are
emerging as a valuable translational model that could help validate biologically relevant targets and assist the
clinical development of novel therapeutic strategies for gastric cancer.
More than 30% of PDXs generated from gastric carcinoma samples developed human B-cell lymphomas instead
of gastric cancer. These lymphomas were monoclonal, Epstein Barr Virus (EBV) positive, originated tumorigenic
cell cultures and displayed a mutational burden and an expression profile distinct from gastric adenocarcinomas.Received 30 November 2017; Revised 6 February 2018; Accepted 14 February 2018
© 2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
access articleunder theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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444 Rituximab Prevents Human-Derived PDX Lymphomas Corso et al. Neoplasia Vol. 20, No. xx, 2018The ability of grafted samples to develop lymphomas did not correlate with patient outcome, nor with the
histotype, the lymphocyte infiltration level, or the EBV status of the original gastric tumor, impeding from
foreseeing lymphoma onset. Interestingly, lymphoma development was significantly more frequent when primary
rather than metastatic samples were grafted.
Notably, the development of such lympho-proliferative disease could be prevented by a short rituximab treatment
upon mice implant, without negatively affecting gastric carcinoma engraftment.
Due to the high frequency of human lymphoma onset, our data show that a careful histologic analysis is
mandatory when generating gastric cancer PDXs. Such care would avoid misleading results that could occur if
testing of putative gastric cancer therapies is performed in lymphoma PDXs. We propose rituximab treatment of
mice to prevent lymphoma development in PDX models, averting the loss of human-derived samples.
Neoplasia (2018) 20, 443–455Introduction
Recent clinical experience suggests that several prerequisites are mandatory
for the success of a targeted therapy: i) a precise molecular annotation of
tumors, to identify possible key targets; ii) the proper selection of patients
that could benefit from that therapy; iii) the validation of the true biological
relevance of these targets in the context of a specific tumor type; iv) the
validation of the inhibitor(s) of the identified target(s) that is/are more
efficient in that particular context; v) the identification of molecular
alterations predicting responsiveness to treatment.
At the moment, the best strategy to fulfill all of the above
mentioned prerequisites is the use of Patient-Derived Xenografts
(PDXs), entailing subcutaneous implantation of fresh cancer samples
in immunocompromised mice, subsequently expanded to generate a
molecularly annotated study population that can be randomized for
prospective treatment with molecular therapies.1,2
In patients affected by gastric tumors, the use of targeted therapies
is much less common than in other cancer patients, with only two
molecular drugs approved so far, namely Trastuzumab and
Ramucirumab.3–5 Pre-clinical models such as PDXs could help
validate biologically relevant targets and assist the clinical develop-
ment of novel combination strategies for this disease.6
PDXs are generated in mice lacking an active immune system that
show a relatively high frequency of lymphoproliferative diseases and
are vulnerable to T-cell-controlled infections, in particular to the
Epstein Barr Virus (EBV).7,8 This virus (affecting around 90% of
humans) can infect both immune (human B-cells, T-cells, NK cells)
and epithelial cells,9 where it persists for life.10 In humans, EBV is
responsible not only for infectious mononucleosis but it is also
associated with malignancies, such as nasopharyngeal and gastric
carcinoma, and lymphoproliferative diseases, like Hodgkin lympho-
ma, Burkitt lymphoma, and lymphomas in immune-depressed
patients.10 Here, we report that more than 30% of PDXs generated
from gastric tumor samples developed EBV-positive lymphomas of
human origin instead of gastric carcinomas. Interestingly, the ability
of grafted samples to develop lymphomas did not correlate with the
amount of lymphocytic infiltration of the original tumor or with EBV
positivity, while it was significantly higher when primary rather than
metastatic samples were grafted. Importantly, the development of
these lympho-proliferative diseases could be prevented by mice
treatment with rituximab upon grafting, thus avoiding the loss of
human-derived adenocarcinoma samples.Materials and Methods
Specimen Collection
Gastric tumor samples and matched normal samples were obtained
from patients undergoing surgery in 12 Italian Hospitals (Supplemen-
tary Materials and Methods). All patients provided informed consent;
samples were collected and the study was conducted under the approval
of the Review Boards of all the Institutions. Clinical and pathologic data
were entered and maintained in our prospective database. All the
samples have been anonymized before being shipped to Candiolo. No
references to the patients can be inferred from the immunohistochem-
ical and molecular characterization presented in the work.
PDX Generation
Gastric cancer material from Torino Hospitals was collected in
medium 199 supplemented with 100 μg/mL levofloxacin, stored at
4°C and received within few hours from surgical resection. Gastric
cancer material from other Italian Hospitals was collected in IGL-1®
preservation medium supplemented with 100 μg/mL levofloxacin,
stored at 4°C and received within 24 hours from surgical resection. At
Candiolo Cancer Institute each sample was cut into 25- to 50-mm3
pieces in antibiotic-containing 199 medium; some of the pieces were
incubated overnight in RNAlater and then frozen at −80°C for
molecular analyses; one piece was fixed in Formalin; 2 pieces were
coated in Matrigel (BD Biosciences) and implanted in two/three
different 4/6-week-old female NOD/SCID mice. After mass
formation, tumors were passaged and expanded for at least 2
generations. Tumor size was evaluated by caliper measurements and
the approximate mass volume was calculated using the formula 4/
3π .(d/2)2.D/2, where d is the minor tumor axis and D is the major
tumor axis. The genetic identity between the original tumor and the
corresponding PDX was evaluated by short tandem repeat profiling
(Cell ID, Promega, Madison, WI, USA). CRC PDXs were
established as described in.11 If not differently specified in the text,
the different analyses have always been performed on first passage
PDXs. Tumor growth rate was calculated using the formula (Vf-Vi)/
T, where Vf is the final volume, Vi is the initial volume, T is the time
(number of days from the initial and the final measurements).
All animal procedures were approved by the Ethical Commission
of the Candiolo Cancer Institute (Candiolo, Torino, Italy), and by
the Italian Ministry of Health.
Figure 1. B-cell lymphomas originate from gastro-esophageal adenocarcinomas implanted in NOD/SCID mice. A. Fresh surgical gastric
adenocarcinoma samples were subcutaneously implanted in NOD/SCID mice. The pathological evaluation of 124 established first
generation PDXs revealed that 77 were gastric adenocarcinomas (62%), 42 were lymphomas (34%) and 5 were mixed tumors, presenting
both gastric and lymphoma tissues in the same tumor mass (4%). B. Haematoxylin and Eosin (H&E) staining of three representative
primary gastric tumors (left panels) and the derived PDXs, which were diagnosed as large cell lymphomas (right panels). C. H&E staining of
a primary gastric tumor (left panel) and the derived mixed PDX (right panel), showing epithelial gastric tumor cells interspersed among
lymphoma cells. D. Representative immunohistochemical analysis of one lymphoma PDX and of one mixed PDX derived from primary
gastric cancers. Pan-cytokeratin, CD20, CD79 and MIB (KI-67) staining were performed. As shown, lymphoma cells were pan-cytokeratin
negative, CD20 and CD79 positive, and exhibited a high MIB-positive score.
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Genomic DNA was isolated using the Relia Prep gDNA Tissue
Miniprep System (Promega). Total RNA was extracted using the
miRNeasyMini Kit (Qiagen) and quality checked by measuring the
28S/18S ribosomal RNA ratio with an Agilent 2100 Bioanalyzer
(Agilent Technologies). DNA and RNA concentrations werequantified using a Nanodrop 1000 Spectrophotometer (Thermo
Fisher Scientific).
Microarray Data Generation
Synthesis of cDNA and biotinylated cRNA (from 500 ng total
RNA) was performed using the IlluminaTotalPrep RNA
Figure 2. Lymphoma onset does not correlate with the degree of lymphocyte infiltration or with the histotype of the original gastric tumor
or with patient outcome. A. The Boxplot reports the distribution of human CD20 expression level, extrapolated from gene array analysis, in
primary patients’ gastric tumors originating either Gastric or Lymphoma PDXs, and in the corresponding Gastric or Lymphoma PDXs
CD20 expression level (directly correlated with the amount of tumor infiltrating lymphocytes) was not significantly different in patients
gastric tumors originating either Gastric or Lymphoma PDXs (P = .1179, Wilcoxon test). As expected, gastric PDXs showed few human
tumor infiltrating lymphocytes, while lymphoma PDXs displayed the highest CD20 expression level (P = .0002, Wilcoxon test). B. Upper
graph: histotypes of primary patients’ gastric carcinomas implanted in mice (according to Lauren classification); lower graph: histotypes
of patients’ gastric carcinomas originating Lymphoma PDXs. As shown, lymphoma PDXs originated from the different histotypes. NR=
Lauren Classification not reported. No significant difference in lymphoma onset between diffuse and intestinal histotypes was found (P=
0.5457, Fisher's exact test). C. The graph represents the follow up (updated at January 2017) of donor patients undergoing surgery
between 2013 and 2015. Among the patients whose tumor originated a Lymphoma PDX, 8 out of 33 (for whom follow up was available
relapsed (24%). Among patients whose tumor originated a Gastric PDX, relapse was observed in 15 out of 45 patients (33%). The
difference was not statistical significant (P = .7828; Fisher’s exact Test).
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Figure 3. Genomic and transcriptomic analysis of PDX lymphomas. A. Targeted sequencing of a panel of 250 genes was performed on 35
gastric PDXs and 18 lymphoma PDXs. The graph represents the number of COSMIC mutations identified in each PDX. Mutational burden
was significantly higher in gastric PDXs compared to lymphomas (****P b .0009, Unpaired t-test). B. Karyotype of cells derived from a
lymphoma PDX. Arrows indicate the trisomy of chromosome 9 (vertical arrow) and the t(X;18)(q25;q21.3) translocation (horizontal arrow).
C. Unsupervised hierarchical clustering performed on transcriptomic analysis of 66 gastric PDXs and 17 lymphoma PDXs. The analysis
revealed the strong partition of the two PDX subgroups.
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protocol. Quality assessment and quantitation of cRNAs were
performed with Agilent RNA kits on a Bioanalyzer 2100 (Agilent).Hybridization of cRNAs (750 ng) was carried out using Illumina
Human 48k gene chips (Human HT-12 V4 BeadChip). Array
washing was performed by Illumina High Temp Wash Buffer for 10′
Figure 4. Lymphoma PDXs are all EBV positive and display monoclonal Ig Heavy Chain rearrangements. A. EBV status was assessed in
Gastric and Lymphoma PDXs through Real-Time quantification on genomic DNA, according to the protocol adopted by the Laboratory
Medicine of the Hospital. PDXs were classified as EBV high (with high EBV burden, N1000, Equivalent EBV Genomes/100000 cells (gEq ×
10e4 cells), EBV intermediate (75-1000 gEq × 10e4 cells) or EBV low/neg (b75 gEq × 10e4 cells). All the analyzed Lymphoma PDXs (n =
24) displayed high EBV burden, compared to 3% of the Gastric PDXs (n = 30). B. Representative in-situ hybridization (ISH) for the Epstein
Barr Virus encoded RNA (EBER) in a patient’s gastric carcinoma (upper part) and in the corresponding lymphoma PDX (lower part). While
only rare EBV+ cells were detected in the patient’s sample, strong positivity was observed in the lymphoma. C. Clonality of the B cell
lymphoproliferative processes was evaluated in 14 representative Lymphoma PDXs. PCR amplification of rearranged VDJ segments (FR1-
JH, FR2-JH and FR3-JH) in the hypervariable region of the immunoglobulin heavy chain, using multiple primers that hybridize with
conserved regions in the genes, was performed on Lymphoma PDX gDNAs. The DNA quality was checked for all samples using the p53
control gene. C-: PCR performed on genomic DNA of a patient without monoclonal Ig heavy chain rearrangement (negative control); C+:
PCR performed on genomic DNA of a patient with monoclonal Ig heavy chain rearrangement (positive control). As shown, all the
Lymphoma PDXs displayed monoclonal Ig heavy chain rearrangements in at least 1 PCR reaction.
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Figure 5. Lymphoma PDXs arise at higher frequency from primary tumors compared to metastases. A. Percentage of Lymphoma PDXs
onset in a PDX platform obtained from NOD/SCID mice implant of liver metastases from colorectal cancer (7/246, left graph) or of primary
colorectal tumors (25/195, right graph). (P b .0001, Fisher's exact test). B. Immunohistochemical analysis of two representative
lymphomas (one lymphoma –upper figures- and one Mixed PDX –lower figures-) derived from primary colorectal cancers. H&E, pan-
cytokeratin and CD20 staining are shown.
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Biosciences). Hybridized arrays were stained and scanned in a
Beadstation 500 (Illumina).
Microarray Data Preprocessing and Statistical Analysis
Probe intensity data were extracted using the Illumina Genome Studio
software (Genome Studio V2011.1). Probes were filtered to select those
showing detectable signal (detection P value = 0) in at least one sample.
Hierarchical clustering of the samples was performed on Euclidean
distance with pvclust package12 in R bioconductor13,14 considering
the top 1000 most variables probes.
Analysis of IG Heavy Chain Rearrangement
Rearrangements in the immunoglobulin heavy chain gene (IgH)
were analyzed using the IgH Rearrangements Molecular Analysis Kit
(Master Diagnòstica, Spain) according to the manufacturer’s
instructions. This kit allows detection of clonality in B cell
lymphoproliferative processes by PCR amplification of rearrangedVDJ segments (FR1-JH, FR2-JH and FR3-JH) in the hypervariable
region of IgH, using multiple primers that hybridize with conserved
regions in the genes. The DNA quality was checked for all samples
using the p53 control gene. PCR products were evaluated by
heteroduplex analysis and electrophoresis in polyacrylamide gels
(Criterion precast gel, BIO-RAD), stained with SYBR Safe (Thermo
Fisher Scientific) and visualized under UV light. When DNA is
amplified from a clonal lymphoid population, the resulting fragments
are all identical in size and sequence, giving a single band.
EBV Evaluation
The detection and quantification of EBV DNA were performed
using the EBV Q-PCR Alert KIT (ELITechGroup S.p.A., Italy). The
real-time amplification assay was carried out on ABI 7300 Real-Time
PCR System instrument (Applied Biosystems, USA). EBV ISH was
performed using the Bond™ Ready-to-Use ISH EBER Probe and the
L Bond™ Ready-to-Use Anti-Fluorescein Antibody (Leica Biosys-
tems, Newcastle Ltd, United Kingdom).
Figure 6. Rituximab treatment prevents lymphoma onset without affecting Gastric PDX engraftment. A. A Lymphoma PDX (GTR0134)
was subcutaneously implanted in 12 NOD/SCIDmice. Four days after implant, 3 animals were treated with physiologic solution (‘Vehicle’),
3 with Rituximab i.p. 25 mg/kg, 3 times/week for 1 week (‘Ritux i.p.1w’), 3 with Rituximab i.p. 25 mg/kg, 3 times/week for 1 week and once
a week for the following 3 weeks (Ritux i.p.4w), 3 with Rituximab i.v. 10 mg/kg, 3 times/week for 1 week (Ritux i.v.1w). The graph shows
the tumor growth curves from the day of implant (day 0). Rituximab treatment completely inhibited lymphoma growth inmice. B. A gastric
PDX (GTR0108) was subcutaneously implanted in 12 NOD/SCID mice. Four days after the implant, mice were divided in 4 groups and
treated as in A. The graph shows the tumor growth curves from the day of implant (day 0). Rituximab treatment did not hamper gastric
carcinoma growth. C. Gastric tumors received fromMarch to August 2016 were implanted in at least 2 NOD/SCID mice; one of themwas
untreated (‘NT’), one was treated with Rituximab i.p. 25 mg/kg 3 times/week for 1 week and once a week for the following 3 weeks (Ritux).
The graph reports the percentages of Gastric, Lymphoma and Mixed PDX onset in mice undergoing the different treatments. As shown,
Rituximab treatment completely prevented the onset of lymphomas (18/18 Gastric PDXs in the Rituximab group). D. The gastric tumor
from patient GTR0271 (upper panels) originated a Gastric PDX when grown in a Rituximab-treated mouse (middle panels) and a
Lymphoma PDX when grown in an untreated animal (lower panels). H&E, pan-cytokeratin and CD20 staining confirmed the different
histology of the PDXs. The EBV score, negative in the donor tumor and in the Gastric PDX and highly positive in the Lymphoma PDX, is
also reported in the figure.
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Animals treated with Rituximab received the drug 4 days after the
subcutaneous (s.c.) implant of the tumor mass, with the following
regimens: (i) Rituximab i.p. 25 mg/kg, 3 times/week for 1 week; (ii)Rituximab i.p. 25 mg/kg, 3 times/week for 1 week and once a week
for the following 3 weeks; (iii) Rituximab i.v. 10 mg/kg, 3 times/week
for 1 week. Rituximab was provided by the Hospital Pharmacy that
collected small amount of drugs left over after treating patients.
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Immunohistochemistry was performed on FFPE tissue sections
using an automated slide instrumentation platform DAKO and the
following primary antibodies: pan-Cytokeratin, CD3, CD20, CD30,
CD45, Bcl-2, Bcl-6, ALK1 (DAKO, Carpinteria, CA); CD5, CD10
(Novocastra, Newcastle upon Tyne, England); Cyclin D1 (Thermo
Fischer Scientific, Waltham, MA, USA). Antibody dilutions are
reported in Supplementary Table 1. Deparaffinization, rehydration,
and target retrieval were performed in the PT Link (Dako PT100).
Slides were then processed on the Autostainer Link 48 (Dako AS480)
using an automated EnVision FLEX (DAKO) staining protocol.
Positive and negative controls were included for each immunohis-
tochemical run. Pictures were acquired with the Leica Assistant Suit
(LAS EZ) Software. Uneven illumination was corrected using a
control image as described in.15
Lymphoma Cell Lines Culturing
Lymphoma cells were derived from lymphoma PDXs as described
in16 for Gastric PDX-derived cells.
Cytogenetic and Fluorescence In Situ Hybridization (FISH)
Analysis
Cytogenetic analysis was performed on the PDX lymphoma cells.
Ten G-banded metaphases were analyzed, and the karyotype was
described according to the International System for Human
Cytogenetic Nomenclature.17 FISH analysis was performed to
evaluate the BCL2, MALT2 and IGH gene status. For this purpose,
the following probes were used: ZytoLight® SPEC BCL2 Dual Color
Break Apart Probe (ZytoVision GmbH, Germany), ZytoLight®
SPEC MALT1 Dual Color Break Apart Probe (ZytoVision GmbH)
and IGH Breakapart Probe (Cytocell, Cambridge UK). One hundred
nuclei were analyzed.
Genomic Sequencing
DNA extracted from PDX models along with a sample of normal
germline DNA from each patient were utilized for next generation
sequencing. Using standard methods, Illumina sequencing libraries
were generated and subjected to hybrid capture with a focused
targeted bait set of 243 genes selected based upon their alteration in
prior studies of gastroesophageal cancer. Somatic events were
identified with MuTect v1.1.418 and Indelocator (http://www.
broadinstitute.org/cancer/cga/indelocator). Additionally, sequencing
was performed on a germline DNA sample from NOD-SCID mice
and putative somatic alterations detected in PDXs that were also
identified in murine DNA were filtered and removed.
Statistics
Statistical Analysis. Statistical testing was performed with
GraphPAD PRISM Software 7.02, using the test indicated in Figure
Legends. Statistical significance: ns = not significant; *P b .05; **P b
.01; ***P b .001; ****P b .0001;.
Results
Onset of Human B Cell Lymphomas Upon Implant of Gastric
Carcinomas
We established a platform of 124 PDXs in NOD-SCID mice by
subcutaneous transplantation of fresh surgical gastric tumor samples
(Figure 1A). All the tumors grown in mice were histologically
evaluated; around 34% of them, at the first generation in mice, didnot resemble the original tumor but rather displayed features of
lymphomas (Figure 1, A and B). Histologically, most were classified
as large cell lymphomas, being populated by mononuclear cells,
ranging from small lymphocytes or plasma cells to large atypical
lymphoid cells with pleomorphic nuclei and abundant basophilic
cytoplasm, resembling lymphoblastoid cells (Figure 1B). In 4% of
cases, we detected foci of carcinoma cells dispersed among non-
epithelial cells (subsequently referred as ‘Mixed PDXs’ (Figure 1, A, C
and D).
As it is known that NOD SCID mice can develop murine
lymphomas at high frequency, we evaluated the species of origin of
the neoplastic cells. Short tandem repeats (STR) analysis of the PDX
and of the respective original gastric tumor showed that they shared
the same STRs (representative examples are shown in Supplementary
Figure 1), proving that the lymphomas were patient-derived.
Moreover, as displayed in Figure 1D, these tumors were reactive
with antibodies specifically recognizing the human CD20 antigen
(18/18 analyzed samples), thus confirming that they derived from
human B-lymphocytes. As expected, all the lymphomas were negative
for a pan-type cytokeratin staining and showed positivity for CD79,
confirming the B-cell derivation of tumor cells (Figure 1D).
Moreover, lymphomas displayed a high MIB-1 (KI-67) index,
indicative of a high proliferation rate (Figure 1D). This is consistent
with the observed growth kinetic; indeed, lymphoma PDXs grew
significantly faster than PDXs maintaining the carcinoma histology,
as the average tumor growth rate in lymphoma PDXs was 70.7 mm3/
day, while in Gastric PDXs it was 24.8 mm3/day (P = .00016;
Supplementary Figure 2A).
A deeper immunophenotyping of the samples revealed that the
developed lymphomas contained CD3/CD5 negative large B
lymphoma cells and a minority of CD3/CD5 positive small reactive
T Lymphocytes, as frequently found in human B cell lymphomas.19
Moreover, lymphoma cells were CD30 and Bcl2 positive, CD10,
ALK1, CyclinD1 and Bcl-6 negative (Supplementary Figure 2B).
During the generation of our PDX platform, usually the patient-
derived gastric carcinoma samples have been implanted in parallel
into two mice. In nearly all cases, first generation PDXs developed
either carcinomas or lymphomas; however, in 5 cases the same sample
generated one gastric carcinoma (counted in the Gastric PDX group)
and one lymphoma (counted in the Lymphoma PDX group)
(Supplementary Figure 3).
Lymphoma Onset Does Not Correlate With the Level of
Lymphocyte Infiltration, the Histotype of the Original Gastric
Tumor, or With Patient Outcome
As PDX lymphomas originate from human lymphocytes, we
hypothesized the existence of a relationship between the number of
lymphocytes (TILs) infiltrating the original tumor and lymphoma
development in mice. We thus performed transcriptomic analysis of
the surgically removed gastric tumors and analyzed CD20 expression.
As shown in Figure 2A, no correlation was observed between the
amount of B lymphocytes present in the stroma of the gastric
carcinoma and lymphoma onset, suggesting that the amount of
immune cells infiltrating the tumor is not directly correlated with the
probability of developing lymphomas.
Similarly, no significant correlation was found between the
histotype of the original gastric tumor and the onset of PDX
lymphomas; indeed, as shown in Figure 2B, lymphomas originated
from all the Lauren’s histotypes (intestinal, diffuse or mixed tumors),
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patient outcome. Follow up of patients undergoing surgery between
2013 and 2015 revealed that their relapse rate was independent from
the type of originated PDX (Figure 2C).
Genomic and Transcriptomic Analysis of PDX Lymphomas
To further characterize lymphoma PDXs we performed genetic and
transcriptomic analyses. Genomic sequencing of a panel of 250 genes
revealed the presence of a significant number of genomic alterations,
although at a significantly lower level compared to gastric carcinoma PDXs
(Figure 3A). Interestingly, all the analyzed lymphomas (20/20) harbored at
least one loss-of-function mutation in ARID1A/B or in ARID2 genes,
components of the SWI-SNF chromatin remodeling complex, which
takes part in somatic cells reprogramming.20,21 Interestingly, ARID1Ahas
been already reported as a recurrently mutated gene in human Follicular
Lymphoma22 and in Diffuse large B-cell lymphoma.23
Cytogenetic analysis of lymphoma cells evinced the presence of
chromosomal aberrations, such as the trisomy of chromosome 9 and
the t(X;18)(q25;q21.3) translocation shown in Figure 3B. FISH
analysis revealed the hemizygous loss of BCL2 gene (18q21.3) as a
consequence of the t(X;18) translocation.
Unsupervised hierarchical clustering performed on transcriptomic
analysis of both lymphoma and carcinoma PDXs completely
separated lymphoma propagation from gastric cancer propagation,
further proving their different cellular origin (Figure 3C).
Finally, several cell lines were derived in culture from lymphoma
PDXs; these cells were able to indefinitely grow in vitro and to
originate tumors when re-injected in mice (Supplementary Figure 4).
Lymphoma PDXs are EBV Positive and Display Monoclonal
Immunoglobulin Heavy Chain (IgH) Rearrangements
As lymphomagenesis in immune-depressed patients is known to be
related with EBV positivity, we assessed the EBV status of lymphoma
PDXs. All the analyzed lymphomas turned out strongly EBV positive
(Figure 4A); however, no correlation was observed between EBV
positivity of primary tumors and lymphoma onset. Indeed, two
primary tumors that were intensely positive for the virus originated
gastric PDXs and not lymphomas (data not shown); conversely, most
lymphomas derived from gastric tumors that were EBV negative,
according to routine Real Time scoring procedures (Supplementary
Table 2). In order to understand if EBV negative scoring of these
tumors was due to the paucity of EBV+ cells within the gastric
carcinoma tissue, we performed in-situ hybridization (ISH) for the
Epstein Barr Virus encoded RNA (EBER), which is abundantly
expressed in latent EBV infection.24 As shown in Figure 4B, rare EBV+
cells could be detected in some gastric carcinomas that originated
lymphoma in immunocompromised mice. However, no EBV+ cells
could be detected in the slices of other gastric carcinomas generating
lymphoma (data not shown). We hypothesize that in EBV cases
scored negative by ISH, rare positive cells could be present in other
parts of the tumor, suggesting that the analysis of the whole
carcinoma should be performed to definitively assess the presence of
EBV+ lymphocytes. When the presence of EBV DNA was
investigated (by real-time-based assays) in white blood cells obtained
from gastric cancer patients, no significant difference in viral copies
was observed between those which originated gastric or lymphoma
PDXs (not shown). Altogether, these results indicate that the EBV
status of cells present in the original tumor, cannot be routinely
exploited to predict lymphoma occurrence in mice.To evaluate the clonal origin of these lymphatic neoplasms we
looked for IgH rearrangements in the neoplastic cells. As shown in
Figure 4B, most of the lymphomas displayed a clonal IgH
rearrangement, proving their monoclonal origin. However, no IgH
monoclonal rearrangement could be detected in the corresponding
primary gastric tumors or in patient’s blood (data not shown).
Lymphomas Originate at Lower Frequency From Metastatic
Than Primary Tumors
As the gastrointestinal mucosa is rich in immune cells (and among
them of B lymphocytes), we wondered if lymphomagenesis in PDXs
might be influenced by the tissue from which the tumor is surgically
removed. Since metastatic gastric PDXs were not present in our
platform, we took advantage from colon cancer PDXs available in our
Institute, derived from both primary and liver metastatic tumors.25
While only 3% of grafted metastatic colon tumors generated human
lymphomas (7/246), this happened only in around 13% of primary
colon cancer PDXs (25/195, P b .0001, Fisher's exact test) (Figure 5A).
Also in these cases all the tested lymphomas were CD20+ (Figure 5B)
and strongly EBV+ (N1000 Equivalent EBV Genomes/100000 cells,
data not shown).
Lymphomagenesis in PDXs is Sensitive to Rituximab Treatment
Preclinical and clinical experience has shown that human lymphomas
are sensitive to treatment with rituximab, an anti-CD20 monoclonal
antibody.26,27 We thus verified if rituximab treatment could impair
lymphoma growth in mice. As shown in Figure 6A, when the drug was
administered intra-peritoneum for 4 weeks, starting 4 days after
implantation of Lymphoma PDXs, it completely impeded lymphoma
growth. The same result was obtained with a 1-week treatment (intra-
peritoneum or intra-vein administration). On the other hand, rituximab
treatment did not hamper the growth of gastric carcinomas (Figure 6B).
Interestingly, in a case where the engrafted tumor gave rise to a Mixed
PDX (carcinoma and lymphoma in different areas of the tumor mass
(Supplementary Figure 5, middle panels), rituximab treatment after
re-implantation allowed growth of a tumor with features of pure
adenocarcinoma (Supplementary Figure 5, lower panels). Rituximab
treatment thus succeeded in rescuing PDX models from EBV
positive contaminant B-cells.
We also wondered if rituximab might be used in a preventive
setting, to avoid the onset of lymphomas, thus increasing the
percentage of carcinoma engraftment. From March to August 2016
each received tumor was therefore implanted in at least 2 mice, one of
them treated for 4 weeks with rituximab, starting at day 4 after
implantation. Among the rituximab-treated mice, none developed
lymphomas (Figure 6C), while the rate of gastric PDX engraftment
was not significantly different between treated and untreated mice
(data not shown). Interestingly, the same primary gastric tumor could
originate a lymphoma when grafted in the untreated mouse and a
gastric carcinoma when grown in the rituximab-treated mouse
(Figure 6D). This demonstrates that the gastric cancer samples
originating lymphoma PDXs, in absence of rituximab, are not devoid
of engraftment potential and suggests that rituximab treatment can be
used to prevent lymphomagenesis and increase carcinoma engraft-
ment rate.
Discussion
Differently from other tumors, for which many therapeutic options
are currently available, only two target therapies have been approved
Neoplasia Vol. 20, No. xx, 2018 Rituximab Prevents Human-Derived PDX Lymphomas Corso et al. 453for gastric cancer so far.3–5 Over the past years, many molecular drugs
entered clinical trials for this kind of cancer but, with the exception of
Trastuzumab and Ramucirumab, they all failed, suggesting the need for
a more accurate patient selection and for more solid preclinical bases.6
The use of PDXs as an emerging translational model for cancer
research has raised interest in the last years,28 and could help improve
gastric cancer therapy. Indeed, PDX models usually retain the
histologic and genetic features of the tumor of origin and have been
shown to be predictive of clinical outcome.1 Therefore, they are
widely used to perform preclinical trials evaluating drug response and
to identify biomarkers and novel therapeutic targets. PDX generation
requires the close interaction between surgeons, pathologists and
researchers, as tumor engraftment demands accurate manipulation of
the samples and very strict timing. Nevertheless, the ability of the
tumor to engraft varies among tumor types.28 Different non-
immunocompetent strains of mice can be used for this procedure, all
of them offering pro and cons. The most immune-depressed ones
usually display a higher graft rate, but also a higher propensity to
develop lymphoproliferative diseases. Formerly, lymphomas of mouse
origin were described to take place either in the site of engraftment or
in different organs.29 More recently, in depth analysis of lymphatic
neoplasms generated in mice engrafted with human carcinoma
samples showed that many of them were of human origin.8,30–32 The
onset of tumors of a histotype different from the original one
represents a risk for the correct interpretation of ‘xenotrial’ results.
Indeed, if researchers are not aware of this issue, the potential
development of lymphomas, instead of the awaited carcinomas, could
impact on the results of the preclinical trials evaluating drug activity.
In fact, as expected, the human-derived lymphoproliferative diseases
developed in PDXs do not share with the tumor of origin the
molecular alterations that justify the administration of a certain
targeted therapy. Thus, this could result in the failure of the
‘xenotrial’, not due to the lack of activity of the drug, but rather to
inappropriate PDX inclusion.
In our work we evaluated a platform of gastric PDXs in NOD
SCID mice and found that around 34% of engrafted tumors were
lymphomas of human origin. These tumors have been diagnosed by
the pathologists as large B cell lymphomas and were all strongly
positive for the EBV virus. However, no correlation could be
identified between EBV positivity of the original tumor (or of
patients’ white blood cells) and the onset of lymphomas in mice. Most
EBV+ lymphomas derived from EBV negative gastric carcinomas.
Considering the monoclonal origin of the lymphomas, it is possible
that in some tumors, scored as EBV negative by real-time PCR, the
number of EBV+ lymphocytes was below the detection threshold;
however, these rare genetically/genomically altered lymphocytes
might have had a selective advantage in an immune-depressed
environment. This hypothesis is supported by the identification,
through ISH analysis, of rare EBV+ cells in some gastric tumor
samples originating lymphomas in immunocompromised mice. We
cannot exclude that, in the cases where ISH has not identified EBV+
cells, few positive lymphocytes might be present in other parts of the
tumor and in particular in the small tumor sample implanted in the
mouse. Finally, in two cases, EBV+ gastric carcinomas originated
gastric PDXs and not lymphomas; in these cases it is likely that gastric
epithelial cells (and not lymphocytes) presented latent EBV infection.
Altogether, these results indicate that the EBV status of cells present
in the original tumor cannot be routinely exploited to predict
lymphoma occurrence in mice.We did not find any correlation between lymphoma onset in mice and
clinical outcome of the original patients. Since none of them developed a
lymphoproliferative disease, it is likely that a deep immunodepressive
condition, rarely found in patients, ismandatory to unleash the oncogenic
potential of the altered B cells. It has also to be noted that the life
expectancy of advanced gastric cancer patients, unfortunately, is not often
long enough to allow for lymphoma appearance.
From a molecular and biological point of view we found that
lymphomas: (i) were of monoclonal origin as they presented
monoclonal rearrangements of immunoglobulin heavy chains; (ii)
in some cases displayed evident chromosomal abnormalities; (iii) were
able to originate tumorigenic cell cultures, maintaining the same
molecular features; (iv) displayed a lower mutational tumor burden
compared to gastric adenocarcinomas; (v) always presented mutations
of ARID1/2 genes, frequently identified in follicular and diffuse large B
cells lymphomas; (vi) showed a distinct expression profile compared to
gastric adenocarcinomas; (vii) grew faster than gastric adenocarcinomas.
The presence ofmonoclonal Ig rearrangements is not an absolute sign of
neoplastic transformation as it can be found in pathologies such asMGUS
(Monoclonal Gammopathies of Undetermined Significance). However,
the concomitant identification of monoclonal Ig rearrangements,
chromosomal rearrangements and several DNA point mutations, joined
with the ability of lymphoma PDXs to be serially transplanted, strongly
support the neoplastic origin of these processes.
As B lymphocytes are the cells of origin of these lymphomas, we
expected to find a connection between the amount of B cells infiltrating
the implanted tumor and lymphomas onset. However, this was not the
case as the evaluation of CD20 expressing cells in the primary tumor did
not correlate with the ability to originate lymphomas.
Nevertheless, while the gastro-intestinal mucosa is known to be rich
in immune cells, this is not true for metastatic sites as liver. Since in our
platform we did not have the opportunity to generate PDXs from
metastatic gastric tumors, we took advantage from a colorectal PDX
platform generated in our institute.25 Interestingly, we found that while
primary colo-rectal tumors originated EBV positive lymphomas at a
relatively high frequency (13%), very few lymphoproliferative disorders
of human origin were originated from implanted metastatic tumors.
Since immune cells are much less represented in the liver parenchyma
compared with intestinal mucosa, these experiments suggest that, above
a certain threshold, the immune component of the tumor tissue of
origin might contribute to the lymphogenic potential in mice. In other
words, the number of latent EBV-infected B cells, affecting lymphoma
PDX formation, could vary significantly in tumors of different anatomic
origin, such as stomach, colon, and liver. This novel observation further
reinforces the idea that the microenvironment of tumor cells strongly
conditions the onset of lymphomas.
Finally, as the development of lymphomas rather than carcinomas
results in loss of valuable PDX models, we aimed at preventing their
onset. Rituximab is a monoclonal antibody directed against CD20,
currently used in the clinic to treat B cell lymphomas.26,27 As it does
not react with mouse B lymphocytes, we tested its therapeutic and
preventive ability in our PDXs. Indeed, we show that a short
rituximab treatment, started just after mice transplantation, was able
to prevent lymphoma onset in PDXs without affecting growth of
adenocarcinomas. Moreover, rituximab treatment of mixed (carcino-
ma and lymphoma) samples after re-implantation allowed the growth
of tumors with features of pure adenocarcinoma, providing an
important strategy to successfully rescue PDX models from EBV
positive contaminant B-cells. Choi and colleagues reported that, using
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lymphoma formation during establishment of gastric cancer PDX
models.33 However, changing the mouse strain in already established
PDX platforms is not always possible or recommended, since it is well
known that microenvironment can influence tumor functions.34 As
some works reported that human lymphomas originate from tumor
grafts of several histotypes (although at different frequency),30–32 we
propose rituximab treatments as an efficient and relatively easy
procedure to prevent lymphoma development and to increase
adenocarcinoma engraftment rate in PDX models.
Conclusions
In conclusion, in a wide gastric cancer PDX platform, we show that
30% of immunocompromised mice implanted with gastric tumors
develop human-derived monoclonal lymphomas instead of gastric
cancer, a percentage much higher than the one observed in PDXs
derived from different tumor histotypes. Moreover, we demonstrate
that preventive rituximab treatment impairs lymphomas onset,
without affecting gastric tumor uptake. This is critical to avoid the
execution of preclinical trials on inappropriate material.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2018.02.003.
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